Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 351 of the 354 references it cites were found in a registry or an index.

Clinical Practice Guideline: Allergic Rhinitis

Abstract

Objective: Allergic rhinitis (AR) is one of the most common diseases affecting adults. It is the most common chronic disease in children in the United States today and the fifth most common chronic disease in the United States overall. AR is estimated to affect nearly 1 in every 6 Americans and generates $2 to $5 billion in direct health expenditures annually. It can impair quality of life and, through loss of work and school attendance, is responsible for as much as $2 to $4 billion in lost productivity annually. Not surprisingly, myriad diagnostic tests and treatments are used in managing this disorder, yet there is considerable variation in their use. This clinical practice guideline was undertaken to optimize the care of patients with AR by addressing quality improvement opportunities through an evaluation of the available evidence and an assessment of the harm‐benefit balance of various diagnostic and management options. Purpose: The primary purpose of this guideline is to address quality improvement opportunities for all clinicians, in any setting, who are likely to manage patients with AR as well as to optimize patient care, promote effective diagnosis and therapy, and reduce harmful or unnecessary variations in care. The guideline is intended to be applicable for both pediatric and adult patients with AR. Children under the age of 2 years were excluded from the clinical practice guideline because rhinitis in this population may be different than in older patients and is not informed by the same evidence base. The guideline is intended to focus on a limited number of quality improvement opportunities deemed most important by the working group and is not intended to be a comprehensive reference for diagnosing and managing AR. The recommendations outlined in the guideline are not intended to represent the standard of care for patient management, nor are the recommendations intended to limit treatment or care provided to individual patients. Action Statements: The development group made a strong recommendation that clinicians recommend intranasal steroids for patients with a clinical diagnosis of AR whose symptoms affect their quality of life. The development group also made a strong recommendation that clinicians recommend oral second‐generation/less sedating antihistamines for patients with AR and primary complaints of sneezing and itching. The panel made the following recommendations: (1) Clinicians should make the clinical diagnosis of AR when patients present with a history and physical examination consistent with an allergic cause and 1 or more of the following symptoms: nasal congestion, runny nose, itchy nose, or sneezing. Findings of AR consistent with an allergic cause include, but are not limited to, clear rhinorrhea, nasal congestion, pale discoloration of the nasal mucosa, and red and watery eyes. (2) Clinicians should perform and interpret, or refer to a clinician who can perform and interpret, specific IgE (skin or blood) allergy testing for patients with a clinical diagnosis of AR who do not respond to empiric treatment, or when the diagnosis is uncertain, or when knowledge of the specific causative allergen is needed to target therapy. (3) Clinicians should assess patients with a clinical diagnosis of AR for, and document in the medical record, the presence of associated conditions such as asthma, atopic dermatitis, sleep‐disordered breathing, conjunctivitis, rhinosinusitis, and otitis media. (4) Clinicians should offer, or refer to a clinician who can offer, immunotherapy (sublingual or subcutaneous) for patients with AR who have inadequate response to symptoms with pharmacologic therapy with or without environmental controls. The panel recommended against (1) clinicians routinely performing sinonasal imaging in patients presenting with symptoms consistent with a diagnosis of AR and (2) clinicians offering oral leukotriene receptor antagonists as primary therapy for patients with AR. The panel group made the following options: (1) Clinicians may advise avoidance of known allergens or may advise environmental controls (ie, removal of pets; the use of air filtration systems, bed covers, and acaricides [chemical agents formulated to kill dust mites]) in patients with AR who have identified allergens that correlate with clinical symptoms. (2) Clinicians may offer intranasal antihistamines for patients with seasonal, perennial, or episodic AR. (3) Clinicians may offer combination pharmacologic therapy in patients with AR who have inadequate response to pharmacologic monotherapy. (4) Clinicians may offer, or refer to a surgeon who can offer, inferior turbinate reduction in patients with AR with nasal airway obstruction and enlarged inferior turbinates who have failed medical management. (5) Clinicians may offer acupuncture, or refer to a clinician who can offer acupuncture, for patients with AR who are interested in nonpharmacologic therapy. The development group provided no recommendation regarding the use of herbal therapy for patients with AR.

Overview

Integrity signals

Registry

Crossref · 10.1177/0194599814561600

Cites

351 of 351 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 354 references

Research works printed but not linked: 13

  1. 10.1177/0194599812468849 · DOI · Paper page
  2. National ambulatory medical care utilization estimates for 2006, 2008, Natl Health Stat Report, 8, 1
  3. Oxford Centre for Evidence‐Based Medicine.OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence.http://www.cebm.net/index.aspx?o=5653.Accessed April 24 2014.
  4. 10.1016/S0194-59989770001-9 · doi:10.1016/s0194-59989770001-9 · Paper page
  5. 10.1016/j.otohns.2006.10.032 · DOI
  6. Kapsali T, 1997, Rhinitis is ubiquitous in allergic asthmatics, J Allergy Clin Immunol, 99, S138
  7. Minshall E, 1998, Assessment by nasal biopsy of longterm use of mometosone furoate aqueous nasal spray in the treatment of perennial rhinitis, Otolaryngol Head Neck Surg, 118, 648
  8. 2008, Norvir [package insert].
  9. 2005, Kaletra [package insert].
  10. 2010, Prezista [package insert].
  11. Lombardo G, 2006, Concomitant levocetirizine and montelukast in the treatment of seasonal allergic rhinitis: influence on clinical symptoms, Italian Journal of Allergy and Clinical Immunology, 16, 63
  12. Maddalozzo J, 2013, Complementary and Integrative Therapies for ENT Disorders, An Issue of Otolaryngologic Clinics
  13. Seidman MD, 1999, Allergies and asthma: alternatives in treatment, Hearing Health, 15, 34

Cited by

See all 673

Metadata

Authors
Seidman, M. D., Gurgel, R. K., Lin, S. Y., Schwartz, S. R., Baroody, F. M., Bonner, J. R., Dawson, D. E., Dykewicz, M. S., Hackell, J. M., Han, J. K., Ishman, S. L., Krouse, H. J., Malekzadeh, S., Mims, J. (. W., Omole, F. S., Reddy, W. D., Wallace, D. V., Walsh, S. A., Warren, B. E., Wilson, M. N., & Nnacheta, L. C.
Affiliations
  • Henry Ford Health (US)
  • University of Utah (US)
  • Johns Hopkins University (US)
  • Virginia Mason Medical Center (US)
  • University of Chicago Medical Center (US)
  • Birmingham VA Medical Center (US)
  • Otolaryngology, Private Practice Muscatine Iowa USA
  • Saint Louis University (US)
  • Pomona Pediatrics Pomona New York USA
  • Eastern Virginia Medical School (US)
  • Cincinnati Children's Hospital Medical Center (US)
  • Wayne State University (US)
  • Georgetown University (US)
  • Atrium Health Wake Forest Baptist (US)
  • Morehouse School of Medicine (US)
  • Acupuncture and Oriental Medicine (AAAOM) Annandale Virginia USA
  • Nova Southeastern University (US)
  • Consumers United for Evidence‐based Healthcare Fredericton New Brunswick Canada
  • Louisiana State University (US)
  • American Academy of Otolaryngology — Head and Neck Surgery (US)
Venue
Otolaryngology–Head and Neck Surgery
Publisher
Wiley
Published
2015-02
Volume
152
Issue
S1
Pages
S1-43
ISSN
  • 0161-6439 (ISSN-L)
  • 0194-5998
  • 1097-6817
OpenAlex
W2099583662
Cited by
671
References
354
Citations by year
2026: 34 · 2025: 35 · 2024: 60 · 2023: 50 · 2022: 60 · 2021: 77 · 2020: 65 · 2019: 61 · 2018: 75 · 2017: 67 · 2016: 47 · 2015: 18
FWCI
60.99
Type
journal article
Language
en
Open access
closed
Locations
  • Otolaryngology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Keywords
allergic rhinitis, diagnosis, intranasal corticosteroids, second-generation antihistamines, allergen immunotherapy, allergen avoidance, allergen testing, specific IgE testing, quality of life, quality improvement, variation in care, pediatric allergic rhinitis, health care costs, productivity loss, benefit-harm balance
MeSH terms
Administration, Intranasal, Adolescent, Adult, Complementary Therapies, Child, Child, Preschool, Chronic Disease, Cost-Benefit Analysis, Diagnosis, Differential, Drug Therapy, Combination, Female, Glucocorticoids, Histamine Antagonists, Humans, Immunoglobulin E, Immunotherapy, Male, Phytotherapy, Quality of Life, Referral and Consultation, Turbinates, United States, Acupuncture Therapy, Comorbidity, Prevalence, Cost of Illness, Anti-Allergic Agents, Evidence-Based Medicine, Leukotriene Antagonists, Interdisciplinary Communication, Nasal Surgical Procedures, Rhinitis, Allergic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Practice Guideline: Allergic Rhinitis. https://app.cochat.ai/papers/10.1177/0194599814561600
The paper
Seidman, M. D., Gurgel, R. K., Lin, S. Y., Schwartz, S. R., Baroody, F. M., Bonner, J. R., Dawson, D. E., Dykewicz, M. S., Hackell, J. M., Han, J. K., Ishman, S. L., Krouse, H. J., Malekzadeh, S., Mims, J. (. W., Omole, F. S., Reddy, W. D., Wallace, D. V., Walsh, S. A., Warren, B. E., . . . Nnacheta, L. C. (2015). Clinical Practice Guideline: Allergic Rhinitis. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1177/0194599814561600

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.